Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.12 USD | +2.17% | -0.28% | -19.85% |
05-30 | Bristol-Myers Squibb Says Breyanzi Gets FDA Approval as CAR T Cell Therapy for Mantle Cell Lymphoma | MT |
05-30 | Bristol Myers: FDA approval for Breyanzi | CF |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-19.85% | 81.59B | |
+40.73% | 734B | |
+32.83% | 591B | |
-6.30% | 350B | |
+15.15% | 315B | |
+4.05% | 276B | |
+15.00% | 238B | |
+9.78% | 206B | |
-5.52% | 204B | |
+6.17% | 161B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol-Myers Squibb Gets FDA Accelerated Approval for Breyanzi for Follicular Lymphoma